A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.

NCT07679399 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

222

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Neoplasms Immunotherapy

Interventions

COMBINATION_PRODUCT: Durvalumab plus GEMOX/GC chemotherapy sequentially followed by lenvatinib
DRUG: Capecitabine

Sponsor

Peking Union Medical College Hospital